Gastro-esophageal Reflux Disease (GERD) Completed Phase 4 Trials for Rabeprazole (DB01129)

Also known as: Esophageal Reflux / Gastroesophageal Reflux Disease / Gastrooesophageal reflux disease / Gastro-Oesophageal Reflux Disease / Gastro-esophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD Gastroesophageal Reflux Disease / GERD (Gastroesophageal Reflux Disease) / GERD / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03037606Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated TabletsTreatment
NCT00251732Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)Treatment
NCT00304421Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERDTreatment
NCT00287391Sleep Disorders and Gastroesophageal Reflux Disease (GERD)Treatment
NCT00354757CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor TestingDiagnostic